Related Experiment Video
Updated: Jun 5, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Sitagliptin-induced hemolysis
Ragini Bekur1, M V Nagaraja, K N Shivashankara
1Department of Medicine, Kasturba Medical College, Manipal University, Manipal, India.
Abstract:
Sitagliptin is a newer oral hypoglycemic drug of the dipeptidyl peptidase-IV inhibitor class. It appears to be a promising newer oral hypoglycemic agent. The advantages are the absence of hypoglycemia when used as monotherapy and they cause less gain weight. We report a case of sitagliptin-induced hemolysis, a rare side effect, not reported in the literature. As sitagliptin is widely used in type 2 diabetes mellitus physicians should be aware of the possibility of this rare but potentially serious adverse drug reaction.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Drug toxicity: Idiosyncratic Reactions
Oral Hypoglycemic Agents: Biguanides and Glitazones
Drug toxicity: Drug–Drug Interaction
